Drugs / Idarubicin
last change 11 days ago re-read 8 days ago

Idarubicin

English name idarubicin

Small molecule targets TOP2A via inhibition

Developed for
acute myeloid leukemia · leukemia · myelodysplastic syndrome · acute promyelocytic leukemia · hepatocellular carcinoma · acute lymphoblastic leukemia · acute leukemia · adult acute lymphoblastic leukemia
+55 more · childhood acute myeloid leukemia · acute myeloid leukemia with 11q23 abnormalities · acute myeloid leukemia with t(8;21)(q22;q22) translocation · acute myeloid leukemia, inv(16)(p13.1;q22) · acute myeloid leukemia, t(16;16)(p13.1;q22) · chronic myelomonocytic leukemia · lymphoma · plasma cell myeloma · acute erythroid leukemia · acute myeloblastic leukemia with maturation · acute myeloblastic leukemia without maturation · acute myelomonocytic leukemia M4 · blast phase chronic myelogenous leukemia, BCR-ABL1 positive · myelodysplastic syndrome with excess blasts · myeloid leukemia · refractory anemia with excess blasts in transformation · acute biphenotypic leukemia · acute megakaryoblastic leukemia in adult · acute myeloid leukemia, del(5q31-q32) · acute undifferentiated leukemia · adult acute monocytic leukemia · primary central nervous system lymphoma · therapy related acute myeloid leukemia and myelodysplastic syndrome · acute leukemia of ambiguous lineage · acute monocytic leukemia · acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) · acute myeloid leukemia with minimal differentiation · acute myeloid leukemia, t(8;21)(q22; q22.1) · adult hepatocellular carcinoma · aggressive B-cell non-Hodgkin lymphoma · B-cell acute lymphoblastic leukemia · B-cell non-Hodgkin lymphoma · bilineal acute myeloid leukemia · CD4+/CD56+ hematodermic neoplasm · childhood acute lymphoblastic leukemia · childhood myelodysplastic syndrome · chronic myeloid leukemia · liver cancer · lung cancer · lymphoid leukemia · mixed phenotype acute leukemia · mixed phenotype acute leukemia, B/myeloid · mixed phenotype acute leukemia,T/myeloid · myelodysplastic syndrome associated with isolated del(5q) · myelodysplastic/myeloproliferative disease · myeloproliferative neoplasm · myeloproliferative neoplasm, unclassifiable · non-small cell lung carcinoma · plasma cell neoplasm · soft tissue sarcoma · unilateral retinoblastoma · urinary bladder cancer · urothelial carcinoma · acute myeloid leukemia with multilineage dysplasia · B-cell childhood acute lymphoblastic leukemia
Investigated by
National Cancer Institute (NCI) · M.D. Anderson Cancer Center · European Organisation for Research and Treatment of Cancer - EORTC · PETHEMA Foundation · Fred Hutchinson Cancer Center · Children's Oncology Group
+154 more · Second Affiliated Hospital of Guangzhou Medical University · Centre Hospitalier Universitaire Dijon · City of Hope Medical Center · Genzyme, a Sanofi Company · Goethe University · Hannover Medical School · Institute of Hematology & Blood Diseases Hospital, China · Memorial Sloan Kettering Cancer Center · Nanfang Hospital, Southern Medical University · Samsung Medical Center · Seoul National University Hospital · The First Affiliated Hospital of Soochow University · Assistance Publique - Hôpitaux de Paris · Beijing 302 Hospital · Celgene Corporation · Federal Research Institute of Pediatric Hematology, Oncology and Immunology · First Affiliated Hospital of Zhejiang University · GIMEMA Foundation · Groupe Francophone des Myelodysplasies · Guangdong Provincial People's Hospital · Johann Wolfgang Goethe University Hospital · Navy General Hospital, Beijing · Peking University People's Hospital · Riverside Haematology Group · Shanghai Jiao Tong University School of Medicine · Shanxi Bethune Hospital · Spanish Cooperative Group for the Study and Treatment of Acute Leukemias and Myelodysplasias · St. Jude Children's Research Hospital · Technical University Dresden · The First Affiliated Hospital with Nanjing Medical University · University Hospital, Montpellier · University of Ulm · AbbVie · Acute Leukemia French Association · Arog Pharmaceuticals, Inc. · Astellas Pharma Global Development, Inc. · Bayer · Baylor College of Medicine · Centre Henri Becquerel · Centre Hospitalier Universitaire de Besancon · Cephalon · Chen Suning · Children's Cancer and Leukaemia Group · Children's Hospital of Soochow University · Chinese PLA General Hospital · Chonbuk National University Hospital · Chonnam National University Hospital · Chung-Ang University Hospital · Columbia University · Cooperative Weichteilsarkom Study Group · Deutsche Kinderkrebsstiftung · Deutsche Krebshilfe e.V., Bonn (Germany) · Duke University · Eisai Inc. · Eli Lilly and Company · European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma · Ev. Krankenhaus Essen-Werden · Ewha Womans University · Federation Francophone de Cancerologie Digestive · First Affiliated Hospital of Guangxi Medical University · First Affiliated Hospital, Sun Yat-Sen University · First Hospital of China Medical University · Fujian Medical University · Gateway for Cancer Research · German CML Study Group · German Federal Ministry of Education and Research · German Society for Pediatric Oncology and Hematology GPOH gGmbH · Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria · Grupo Argentino de Tratamiento de la Leucemia Aguda · Guangzhou First People's Hospital · Guerbet · H. Lee Moffitt Cancer Center and Research Institute · HOVON - Dutch Haemato-Oncology Association · Hanyang University Seoul Hospital · all 160 on the full record

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) IDAMYCIN — 1990-09-27 fda.gov ↗

Trials 160 · started per year

today
US approved 1990
4
4
3
7
3
12
6
5
2
3
3
5
1
2
7
2
6
8
4
7
6
4
8
5
3
3
4
5
4
3
9
9
3
199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT07059975 Oct 2025 → Oct 2028 expected childhood acute myeloid leukemia Joanna Yi Recruiting No outcome recorded
Phase 112 trials
Phase 1 NCT05453903 Oct 2022 → Oct 2026 expected acute myeloid leukemia Janssen Research & Development, LLC Active not recruiting No outcome recorded
Phase 1 NCT04190550 Feb 2021 → Jun 2027 expected acute myeloid leukemia National Cancer Institute (NCI) Active not recruiting No outcome recorded
Phase 1 NCT04375631 Dec 2020 → Feb 2027 expected acute undifferentiated leukemia, chronic myelomonocytic leukemia, mixed phenotype acute leukemia, myelodysplastic syndrome Fred Hutchinson Cancer Center Recruiting No outcome recorded
Phase 1 NCT03194932 Jul 2017 → Oct 2020 acute myeloid leukemia St. Jude Children's Research Hospital Completed No outcome recorded
Phase 1 NCT02652871 May 2016 → Jul 2019 leukemia M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1 NCT02632708 Dec 2015 → Dec 2018 overdue therapy related acute myeloid leukemia and myelodysplastic syndrome Servier Active not recruiting No outcome recorded
Phase 1 NCT02236013 Jan 2015 → Jul 2021 acute myeloid leukemia Astellas Pharma Global Development, Inc. Completed No outcome recorded
Phase 1 NCT02028949 Nov 2012 → Nov 2015 cirrhosis of liver, hepatocellular carcinoma Centre Hospitalier Universitaire Dijon Completed No outcome recorded
Phase 1 NCT02870010 Feb 2010 → May 2012 adult hepatocellular carcinoma Centre Hospitalier Universitaire Dijon Completed No outcome recorded
Phase 1 NCT01040559 Dec 2009 → Dec 2011 hepatocellular carcinoma Centre Hospitalier Universitaire Dijon Completed No outcome recorded
Phase 1/215 trials
Phase 1/2 NCT04047641 Oct 2019 → Dec 2027 expected acute biphenotypic leukemia, myelodysplastic syndrome M.D. Anderson Cancer Center Recruiting No outcome recorded
Phase 1/2 NCT02046122 Jul 2014 → Jun 2017 acute myeloid leukemia, myelodysplastic syndrome Duke University Completed No outcome recorded
Phase 1/2 NCT01876953 Sep 2013 → Apr 2018 acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22), acute myeloid leukemia with t(8;21)(q22;q22) translocation City of Hope Medical Center Terminated No outcome recorded
Phase 1/2 NCT01794702 Feb 2013 → Jan 2018 acute leukemia M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1/2 NCT01534702 Jan 2012 → Apr 2013 acute myeloid leukemia Hannover Medical School Unknown No outcome recorded
Phase 1/2 NCT01518556 Jul 2011 → Mar 2025 acute myeloid leukemia Konkuk University Medical Center Completed No outcome recorded
Phase 1/2 NCT01289457 Feb 2011 → Jun 2017 leukemia M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1/2 NCT01305135 Dec 2010 → Jun 2011 myelodysplastic syndrome Groupe Francophone des Myelodysplasies Completed No outcome recorded
Phase 1/2 NCT01141725 Sep 2010 → Nov 2012 acute myeloid leukemia with 11q23 abnormalities, acute myeloid leukemia with t(8;21)(q22;q22) translocation, acute myeloid leukemia, del(5q31-q32), acute myeloid leukemia, inv(16)(p13.1;q22) +2 Fred Hutchinson Cancer Center Completed No outcome recorded
Phase 1/2 NCT00831766 Jun 2009 → Feb 2015 acute myeloid leukemia, myelodysplastic syndrome H. Lee Moffitt Cancer Center and Research Institute Completed No outcome recorded
Phase 267 trials · 1 met primary
Phase 2 NCT07548710 May 2026 → May 2027 expected acute myeloid leukemia Ruijin Hospital Recruiting No outcome recorded
Phase 2 NCT07514832 Apr 2026 → Apr 2028 expected acute myeloid leukemia Beijing 302 Hospital Recruiting No outcome recorded
Phase 2 NCT07228273 Dec 2025 → Jun 2029 expected acute myeloid leukemia, myelodysplastic syndrome OHSU Knight Cancer Institute Recruiting No outcome recorded
Phase 2 NCT07046078 Sep 2025 → Jun 2027 expected acute leukemia of ambiguous lineage, chronic myelomonocytic leukemia, myelodysplastic syndrome Fred Hutchinson Cancer Center Recruiting No outcome recorded
Phase 2 NCT06930105 Sep 2025 → Nov 2027 expected acute lymphoblastic leukemia Xianmin Song, MD Not yet recruiting No outcome recorded
Phase 2 NCT07108530 Aug 2025 → Aug 2027 expected acute myeloid leukemia Shanxi Bethune Hospital Recruiting No outcome recorded
Phase 2 NCT07078591 Jun 2025 → Jun 2030 expected acute myeloid leukemia Beijing 302 Hospital Recruiting No outcome recorded
Phase 2 NCT07564453 Apr 2025 → Dec 2027 expected B-cell acute lymphoblastic leukemia The First Affiliated Hospital of Soochow University Recruiting No outcome recorded
Phase 2 NCT06492408 Jul 2024 → Dec 2028 expected hepatocellular carcinoma Second Affiliated Hospital of Guangzhou Medical University Recruiting No outcome recorded
Phase 2 NCT06492421 Jul 2024 → Dec 2028 expected non-small cell lung carcinoma Second Affiliated Hospital of Guangzhou Medical University Recruiting No outcome recorded
Phase 2/310 trials · 1 met primary
Phase 2/3 NCT07059156 Jun 2025 → Jun 2027 expected adult acute lymphoblastic leukemia Shanxi Bethune Hospital Recruiting No outcome recorded
Phase 2/3 NCT05280444 May 2022 → Jun 2023 hepatocellular carcinoma Zhongda Hospital Unknown No outcome recorded
Phase 2/3 NCT04216771 Jan 2020 → May 2022 acute myeloid leukemia Fujian Medical University Unknown No outcome recorded
Phase 2/3 NCT02671708 Jan 2016 → Feb 2019 acute myeloid leukemia, disease related to hematopoietic stem cell transplant Nanfang Hospital, Southern Medical University Completed No outcome recorded
Phase 2/3 NCT02416388 Jan 2015 → Jul 2025 overdue acute myeloid leukemia University Hospital, Angers Recruiting Met primary
Phase 2/3 NCT02836158 Sep 2010 → Dec 2025 overdue primary central nervous system lymphoma Navy General Hospital, Beijing Recruiting No outcome recorded
Phase 2/3 NCT02657785 Sep 2010 → Dec 2028 expected primary central nervous system lymphoma Navy General Hospital, Beijing Recruiting No outcome recorded
Phase 2/3 NCT00909168 Mar 2008 → May 2009 acute myeloid leukemia University Hospital, Udine, Italy Completed No outcome recorded
Phase 2/3 NCT00111345 Mar 2004 → Mar 2012 myeloid leukemia University Hospital Muenster Unknown No outcome recorded
Phase 2/3 NCT00209833 Jan 1999 → Sep 2005 acute myeloid leukemia, refractory anemia with excess blasts in transformation Hannover Medical School Unknown No outcome recorded
Phase 332 trials · 4 met primary · 3 missed
Phase 3 NCT07232134 Jul 2025 → Jul 2030 expected Down syndrome, acute myeloid leukemia Federal Research Institute of Pediatric Hematology, Oncology and Immunology Recruiting No outcome recorded
Phase 3 NCT05177731 Mar 2022 → Feb 2024 overdue acute myeloid leukemia, chemotherapy-induced toxicity Chen Suning Active not recruiting Met primary
Phase 3 NCT03475121 Jan 2018 → Jan 2023 unilateral retinoblastoma Hospital JP Garrahan Completed No outcome recorded
Phase 3 NCT02688140 Jun 2016 → Jan 2025 acute promyelocytic leukemia Technical University Dresden Completed Met primary
Phase 3 NCT02339740 Jul 2015 → Oct 2020 overdue acute promyelocytic leukemia Children's Oncology Group Active not recruiting Met primary
Phase 3 NCT01802333 Feb 2013 → Jun 2017 acute myeloid leukemia National Cancer Institute (NCI) Completed No outcome recorded
Phase 3 NCT00876031 Jul 2009 → Jun 2022 soft tissue sarcoma University Hospital Tuebingen Completed Missed primary
Phase 3 NCT00866918 Mar 2009 → Jun 2015 acute promyelocytic leukemia Children's Oncology Group Completed No outcome recorded
Phase 3 NCT06211452 Aug 2007 → Mar 2015 childhood acute myeloid leukemia Grupo Argentino de Tratamiento de la Leucemia Aguda Completed Missed primary
Phase 3 NCT00967057 Oct 2002 → Jan 2010 acute leukemia Children's Cancer and Leukaemia Group Completed Met primary
Phase 413 trials · 1 met primary
Phase 4 NCT01873807 May 2013 → Dec 2015 adult acute lymphoblastic leukemia Nanfang Hospital, Southern Medical University Unknown No outcome recorded
Phase 4 NCT02020161 Jun 2012 → Dec 2021 acute promyelocytic leukemia PETHEMA Foundation Unknown No outcome recorded
Phase 4 NCT01987297 Jun 2012 → Dec 2020 acute promyelocytic leukemia Shanghai Jiao Tong University School of Medicine Unknown Met primary
Phase 4 NCT02277847 Mar 2010 → Jun 2017 acute myeloid leukemia Guangdong Provincial People's Hospital Unknown No outcome recorded
Phase 4 NCT01366898 Jun 2007 → Dec 2022 acute lymphoblastic leukemia PETHEMA Foundation Unknown No outcome recorded
Phase 4 NCT00408278 Jul 2005 → Apr 2012 acute promyelocytic leukemia PETHEMA Foundation Completed No outcome recorded
Phase 4 NCT00198978 Jan 2003 → Jun 2011 adult acute lymphoblastic leukemia Goethe University Completed No outcome recorded
Phase 4 NCT00180128 Jan 2000 → Nov 2012 acute promyelocytic leukemia Technical University Dresden Unknown No outcome recorded
Phase 4 NCT00199056 Oct 1999 → Nov 2003 adult acute lymphoblastic leukemia Goethe University Completed No outcome recorded
Phase 4 NCT00465933 Mar 1999 → Aug 2007 acute promyelocytic leukemia PETHEMA Foundation Completed No outcome recorded
Phase not applicable10 trials
— NCT07443592 Mar 2026 → Mar 2031 expected acute lymphoblastic leukemia PETHEMA Foundation Not yet recruiting No outcome recorded
— NCT07131059 May 2024 → May 2026 overdue acute myeloid leukemia Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
— NCT06232694 Jan 2024 → Dec 2027 expected acute myeloid leukemia The First Affiliated Hospital with Nanjing Medical University Recruiting No outcome recorded
— NCT05053425 Oct 2021 → Jan 2023 acute myeloid leukemia LanZhou University Unknown No outcome recorded
— NCT05053386 Oct 2021 → Oct 2022 hepatocellular carcinoma Zhejiang Cancer Hospital Unknown No outcome recorded
— NCT04179929 Nov 2019 → Nov 2026 expected acute lymphoblastic leukemia PETHEMA Foundation Recruiting No outcome recorded
— NCT03390387 Nov 2015 → Nov 2020 childhood acute lymphoblastic leukemia Federal Research Institute of Pediatric Hematology, Oncology and Immunology Unknown No outcome recorded
— NCT01831232 May 2013 → Feb 2015 acute erythroid leukemia, acute megakaryoblastic leukemia in adult, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation +11 Fred Hutchinson Cancer Center Completed No outcome recorded
— NCT01296178 Dec 2010 → Dec 2021 acute myeloid leukemia PETHEMA Foundation Unknown No outcome recorded
— NCT00317408 Apr 2004 → Feb 2014 lymphoma European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma Unknown No outcome recorded
Comparator or background therapy142 trials
Phase 0 NCT01822015 Background Mar 2013 → Dec 2019 acute erythroid leukemia, acute megakaryoblastic leukemia in adult, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation +7 Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University Completed No outcome recorded
Phase 1 NCT06226571 Background May 2024 → Feb 2027 expected acute myeloid leukemia Syndax Pharmaceuticals Active not recruiting No outcome recorded
Phase 1 NCT06001788 Background Feb 2024 → Aug 2026 overdue acute myeloid leukemia with mutated NPM1, acute myeloid leukemia, MLL gene rearrangement Kura Oncology, Inc. Recruiting No outcome recorded
Phase 1 NCT06034470 Background Dec 2023 → May 2026 overdue mixed phenotype acute leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm Fred Hutchinson Cancer Center Active not recruiting No outcome recorded
Phase 1 NCT04250051 Background Dec 2020 → Jan 2022 acute myeloid leukemia, myelodysplastic syndrome Northwestern University Terminated No outcome recorded Stop: Enrollment
Show all 142 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 5

DateIssuerRelease
2018-12-03 Astellas Pharma Inc Results Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) astellas.com ↗
The CRc rate in FLT3mut+ subjects receiving Schedule 2 induction with idarubicin was 66.7%.
2016-12-04 Karyopharm Therapeutics Inc Results Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data at the American Society of Hematology 2016 Annual Meeting karyopharm.com ↗
Phase II Results of Ara-C and Idarubicin in Combination with the Selective Inhibitor of Nuclear Export Compound Selinexor in Patients with Relapsed or Refractory AML
2016-11-07 Karyopharm Therapeutics Inc Results Karyopharm Reports Third Quarter 2016 Financial Results and Highlights Recent Progress karyopharm.com ↗
The SAIL data demonstrate that the selinexor, Ara-C and idarubicin combination achieved compelling response rates and has the potential to be an effective AML treatment option and serve as a bridge to stem cell transplantation in this patient population.
2015-12-07 Karyopharm Therapeutics Inc Results Karyopharm Therapeutics Presents Positive Clinical Data on the Activity of Selinexor in Combination with Other Anticancer Agents across Multiple Hematologic Malignancies at the 2015 American Society of Hematology (ASH) Annual Meeting karyopharm.com ↗
with Ara-C and idarubicin in relapsed or refractory acute myeloid leukemia (AML)
2015-05-21 Karyopharm Therapeutics Inc Results Karyopharm to Present Hematologic Cancer Data on Lead Drug Candidate Selinexor at European Hematology Association Annual Meeting karyopharm.com ↗
An overall response rate of 53% (eight) was achieved based on fifteen evaluable patients and 67% (six) of those patients went on to receive either stem cell transplant or donor lymphocyte infusion.

Evidence & citations 19 cited values

Every value below carries the sentence it was read from. 306 sources stand behind the page.

FieldValueCited text
Known as Idarubicin “Consolidation 6-thioguanine 60 mg/m2/d, 1 to 43 po; prednisone 40 mg/m2/d, on days 1-28 orally; vincristine 1.5 mg/m2/d, days 1, 8, 15, 22; idarubicin 7 mg/m2/d, on days 1, 8,...” NCT06211452 ↗
297

“* FLAG ± Ida regimen: G-CSF injection 300 mcg/m2 QD SC for 5 consecutive days (Days 1-5); fludarabine injection 30 mg/m2 QD IV for 5 consecutive days (Days 2-6); cytarabine...” NCT06387069 ↗

“Standard Chemotherapy includes IA(Idarubicin combined with Cytarabine) or DA(Daunorubicin combined with Cytarabine). IDA is given by venous drip daily at 12mg/m2, or DNR is...” NCT06810791 ↗

“R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion...” NCT02657785 ↗

“R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in...” NCT02836158 ↗

“To further intensify anthracycline dosage without increasing cardiotoxicity, we compared potentially less cardiotoxic liposomal daunorubicin (L-DNR) to idarubicin at a...” PMID 23704089 ↗ May 2013

“Resistant participants will receive a second induction with inotuzumab for B-cell precursor ALL or with FLAG-Ida (fludarabine, cytarabine, idarubicin and granulocyte colony...” NCT07443592 ↗

“Patients will receive 100-200 mg/m2 per day intravenously of cytarabine for 7 days, plus either 45-60 mg/m2 per day intravenously of daunorubicin or 9-12 mg/m2 per day...” NCT03446638 ↗

“Fludarabine and Cytarabine as Continuous Infusion Plus Idarubicin With Granulocyte-Colony Stimulating Factor (G-CSF) Priming for Patients Younger Than 60 Years With Resistant...” NCT00559221 ↗

“A Phase I Study Using Bortezomib (Velcade, Formerly Known as PS-341) With Weekly Idarubicin for the Treatment of Elderly (>/= 60 Years) and Relapsed Patients With Acute...” NCT00382954 ↗

“For FLT3/IDH1 wild-type participants who are eligible for chemotherapy, Anthracycline: Daunorubicin (DNR) 45 mg/m² per day on Days 1-3, or Idarubicin (IDA) 6 mg/m² per day on Days 1-3.” NCT07548710 ↗

Show 287 more sources

Known as 4-Demethoxydaunomycin “4-Demethoxydaunomycin” NCT00801489 ↗
Known as 4-demethoxydaunorubicin “4-demethoxydaunorubicin” NCT00801489 ↗
Known as IDA “The study included 727 older patients with AML (median age, 67 years) treated in two idarubicin (IDA) versus daunorubicin (DNR) Acute Leukemia French Association trials.” PMID 23248249 ↗ Dec 2012
11

“We report on a Phase 2 clinical trial using the novel combination of 2-chlorodeoxyadenosine (2-CDA) (8 mg/m² per d x 5 d) plus idarubicin (Ida) (10 mg/m² per d x 3 d).” PMID 22512017 ↗ Mar 2012

“Idarubicin (IDA) 10mg/㎡ for d1-3 , Ara-c 100mg/㎡ d1-7 , Cyclophosphamide (CTX350mg/㎡ d2, d5)” NCT06529250 ↗

“Continuous infusion of idarubicin (IDA) over 48 hours on days -12 and -11” NCT00002989 ↗

“Intravenous Idarubicin (Ida): 6 mg/m²/day on days 1-3” NCT07108530 ↗

“Idarubicin (IDA): 8 mg/m², days 1, 8, 15, 22.” NCT07059156 ↗

“idarubicin (IDA) IV on days 3 and 4” NCT00002771 ↗

“IDA Idarubicin, NSC-256439” NCT00002549 ↗

“IDA Idarubicin, NSC-256439” NCT00002565 ↗

“Drug: Idarubicin(IDA)” NCT07078591 ↗

“idarubicin (IDA)” NCT00002701 ↗

Show 1 more source

Known as Idamycin ChEMBL registry synonym — accepted as the source's own label CHEMBL1117 ↗
Known as Idamycin pfs ChEMBL registry synonym — accepted as the source's own label CHEMBL1117 ↗
Known as Idarubicin hcl ChEMBL registry synonym — accepted as the source's own label CHEMBL1117 ↗
Known as Idarubicin Hydrochloride ClinicalTrials.gov intervention name — accepted as the source's own label NCT06221683 ↗
3

NCT07059975 ↗

NCT02029950 ↗

NCT05955261 ↗

Known as Idarubicin Hydrochloride for Injection “Drug: Idarubicin Hydrochloride for Injection” NCT05280444 ↗
1

“Drug: Idarubicin Hydrochloride for Injection” NCT05053386 ↗

Known as Idarubicin hydrochloride pfs ChEMBL registry synonym — accepted as the source's own label CHEMBL1117 ↗
Known as Idarubicina ChEMBL registry synonym — accepted as the source's own label CHEMBL1117 ↗
Known as Idarubicine ClinicalTrials.gov intervention name — accepted as the source's own label NCT04087967 ↗
Known as IMI 30 ChEMBL registry synonym — accepted as the source's own label CHEMBL1117 ↗
Known as NSC-256439 “IDA Idarubicin, NSC-256439” NCT00002565 ↗
Known as Zavedos “Idarubicin (Zavedos®) as the reconstituted solution, will be administered slowly by the intravenous route over 60 minutes at 10 mg/m²of body-surface area on day 8 of...” NCT01342692 ↗
4

“Chemoembolization of Non-resectable Non-metastatic Hepatocellular Carcinoma Using Embolization Microspheres (DC Bead™) Loaded With Idarubicin (Zavedos®): Phase 1 Study” NCT02870010 ↗

“Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos®): Phase I Study” NCT02028949 ↗

“administration of Idarubicin (Zavedos®, Pfizer) mixed with Lipiodol (Lipiodol Ultra-Fluid®, Guerbet) in the hepatic artery.” NCT04178642 ↗

NCT01015196 ↗

Action Inhibit “DNA topoisomerase II alpha inhibitor” CHEMBL1117 ↗
1

“to stop DNA from repairing itself” NCT00542971 ↗

Modality Small molecule “oral anthracycline” NCT01958996 ↗
Route Intravenous “idarubicin IV on days 3-5” NCT00002517 ↗
Target TOP2A “DNA topoisomerase II alpha inhibitor” CHEMBL1117 ↗